| Marin Post Acute | |
| 234 N. San Pedro Rd, San Rafael, California 94903 | |
| (415) 479-3450 | |
| Name | Marin Post Acute |
|---|---|
| Location | 234 N. San Pedro Rd, San Rafael, California |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 168 |
| Occupancy Rate | 71.67% |
| Medicare ID (CCN) | 055310 |
| Legal Business Name | Marinidence Opco Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1124178645 |
| Organization Name | RAFAEL CONVALESCENT HOSPITAL |
| Address | 234 N San Pedro Rd, San Rafael, CA 94903 |
| Phone Number | 415-479-3450 |
News Archive
A new study from the Monell Center increases understanding of the biological mechanisms responsible for the nausea and vomiting that often afflict patients undergoing chemotherapy.
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
"Much still needs to be done to get treatment to those who need it and to meet the UNAIDS-endorsed goal to achieve universal access by 2015, according to a new survey examining 25 HIV indicators assessing strategies, tools and policies to get the best HIV treatment to more people, sooner," the Center for Global Health Policy's "Science Speaks" blog reports.
Today's early morning highlights from the major news organizations, including reports about Marilyn Tavenner's nomination to run Medicare and the Catholic bishops' rejection of the Obama administration's contraception plan announced last week.
Cambridge Heart, Inc., today announced that it has received clearance from the U.S. Food and Drug Administration to begin marketing its Microvolt T-Wave Alternans (MTWA) OEM module. The MTWA OEM module is designed to work with existing cardiac stress test platforms distributed by other manufacturers. This FDA 510(k) clearance allows Cambridge Heart to begin marketing the MTWA OEM module integrated with the Q-Stress line of stress systems manufactured by Cardiac Science Corporation, Inc..
› Verified 9 days ago
| NPI Number | 1952849572 |
| Organization Name | MARINIDENCE OPCO, LLC |
| Doing Business As | MARIN POST ACUTE |
| Address | 234 N San Pedro Rd, San Rafael, CA 94903 |
| Phone Number | 415-479-3450 |
News Archive
A new study from the Monell Center increases understanding of the biological mechanisms responsible for the nausea and vomiting that often afflict patients undergoing chemotherapy.
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
"Much still needs to be done to get treatment to those who need it and to meet the UNAIDS-endorsed goal to achieve universal access by 2015, according to a new survey examining 25 HIV indicators assessing strategies, tools and policies to get the best HIV treatment to more people, sooner," the Center for Global Health Policy's "Science Speaks" blog reports.
Today's early morning highlights from the major news organizations, including reports about Marilyn Tavenner's nomination to run Medicare and the Catholic bishops' rejection of the Obama administration's contraception plan announced last week.
Cambridge Heart, Inc., today announced that it has received clearance from the U.S. Food and Drug Administration to begin marketing its Microvolt T-Wave Alternans (MTWA) OEM module. The MTWA OEM module is designed to work with existing cardiac stress test platforms distributed by other manufacturers. This FDA 510(k) clearance allows Cambridge Heart to begin marketing the MTWA OEM module integrated with the Q-Stress line of stress systems manufactured by Cardiac Science Corporation, Inc..
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
A new study from the Monell Center increases understanding of the biological mechanisms responsible for the nausea and vomiting that often afflict patients undergoing chemotherapy.
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
"Much still needs to be done to get treatment to those who need it and to meet the UNAIDS-endorsed goal to achieve universal access by 2015, according to a new survey examining 25 HIV indicators assessing strategies, tools and policies to get the best HIV treatment to more people, sooner," the Center for Global Health Policy's "Science Speaks" blog reports.
Today's early morning highlights from the major news organizations, including reports about Marilyn Tavenner's nomination to run Medicare and the Catholic bishops' rejection of the Obama administration's contraception plan announced last week.
Cambridge Heart, Inc., today announced that it has received clearance from the U.S. Food and Drug Administration to begin marketing its Microvolt T-Wave Alternans (MTWA) OEM module. The MTWA OEM module is designed to work with existing cardiac stress test platforms distributed by other manufacturers. This FDA 510(k) clearance allows Cambridge Heart to begin marketing the MTWA OEM module integrated with the Q-Stress line of stress systems manufactured by Cardiac Science Corporation, Inc..
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 10 |
| Total Amount of Fines in Dollars | $21180 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 10 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 5.84 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 14.75 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 21.74 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.33 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.75 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 16.19 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 99.76 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.68 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 7.6 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 9.72 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.85 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 75.89 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 98.65 | 82.93 |
News Archive
A new study from the Monell Center increases understanding of the biological mechanisms responsible for the nausea and vomiting that often afflict patients undergoing chemotherapy.
Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
"Much still needs to be done to get treatment to those who need it and to meet the UNAIDS-endorsed goal to achieve universal access by 2015, according to a new survey examining 25 HIV indicators assessing strategies, tools and policies to get the best HIV treatment to more people, sooner," the Center for Global Health Policy's "Science Speaks" blog reports.
Today's early morning highlights from the major news organizations, including reports about Marilyn Tavenner's nomination to run Medicare and the Catholic bishops' rejection of the Obama administration's contraception plan announced last week.
Cambridge Heart, Inc., today announced that it has received clearance from the U.S. Food and Drug Administration to begin marketing its Microvolt T-Wave Alternans (MTWA) OEM module. The MTWA OEM module is designed to work with existing cardiac stress test platforms distributed by other manufacturers. This FDA 510(k) clearance allows Cambridge Heart to begin marketing the MTWA OEM module integrated with the Q-Stress line of stress systems manufactured by Cardiac Science Corporation, Inc..
› Verified 9 days ago
San Rafael Healthcare & Wellness Center, Lp Location: 1601 5th Avenue, San Rafael, California 94901 Phone: (415) 456-7170 | |
Pine Ridge Care Center Location: 45 Professional Center Pkwy, San Rafael, California 94903 Phone: (415) 479-3610 | |
Northgate Postacute Care Location: 40 Professional Center Parkway, San Rafael, California 94903 Phone: (415) 479-1230 | |
Professional Post Acute Center Location: 81 Professional Center Parkway, San Rafael, California 94903 Phone: (415) 479-5161 | |